Journal article
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer
M Weischer, BG Nordestgaard, P Pharoah, MK Bolla, H Nevanlinna, LJ Van't Veer, M Garcia-Closas, JL Hopper, P Hall, IL Andrulis, P Devilee, PA Fasching, H Anton-Culver, D Lambrechts, M Hooning, A Cox, GG Giles, B Burwinkel, A Lindblom, FJ Couch Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2012
Abstract
Purpose: We tested the hypotheses that CHEK2*1100delC heterozygosity is associated with increased risk of early death, breast cancer-specific death, and risk of a second breast cancer in women with a first breast cancer. Patients and Methods: From 22 studies participating in the Breast Cancer Association Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC and observed for up to 20 years (median, 6.6 years). We examined risk of early death and breast cancer-specific death by estrogen receptor status and risk of a second breast cancer after a first breast cancer in prospective studies. Results: CHEK2*1100delC heterozygosity was found in 459 patients (1...
View full abstractGrants
Awarded by European Commission